Breast Cancer Treatment
2019 · JAMA · 4,716 citations
https://doi.org/10.1001/jama.2018.19323
A
Adrienne G. Waks
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
215
Papers
8.4K
Citations
22
h-index
35
i10-index
Adrienne G. Waks is an academic researcher from Harvard University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 22, co-authored 183 publications.
ORCID: 0000-0001-5649-7229Papers by this author
worksScalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
2017 · Nature Communications · 1,033 citations
https://doi.org/10.1038/s41467-017-00965-y
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
2018 · Nature Genetics · 235 citations
https://doi.org/10.1038/s41588-018-0287-5
The Immunology of Hormone Receptor Positive Breast Cancer
2021 · Frontiers in Immunology · 171 citations
https://doi.org/10.3389/fimmu.2021.674192
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
2022 · npj Breast Cancer · 39 citations
https://doi.org/10.1038/s41523-022-00429-7
Assessment of the HER2DX Assay in Patients With <i>ERBB2</i>-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
2023 · JAMA Oncology · 34 citations
https://doi.org/10.1001/jamaoncol.2023.0181
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat